An update on immunotherapy for multiple myeloma in 2016
Ignacio Melero Bermejo et al.
Phase Ib dose escalation trial of SAR650984 improves outcomes in relapsed or refractory myeloma
What is the focus of lymphoma research in 2017?
Research on HDACs for multiple myeloma: studying immunological effects and resistance models
Navigating advances in the myeloma landscape over the past couple of years
Saad Z. Usmani